Kwizda Pharma GmbH - BIOSIMILAR G-CSF: COOPERATION ON THREE CONTINENTS

A biosimilar protein that can be acclimated to amusement neutropenia (a ancillary aftereffect of blight chemotherapy) is to be developed by Apotex Inc. of Canada in accord with Intas Biopharmaceuticals Limited (IBPL). Neukine (R), a recombinant granulocyte antecedents aesthetic agency (G-CSF) is already bogus and marketed in India by IBPL. Kwizda Pharma of Austria had been alive with IBPL to advance G-CSF for the European bazaar for some time. Effectively immediately, Kwizda Pharma has transferred all of its rights in IBPL's G-CSF to Apotex. Apotex and IBPL accept accordingly agreed to extend the accord to development of G-CSF for North America (US and Canada).

Dr. Helmut Brunar, VP Research and Business Development of Kwizda Pharma explains the alternate allowances of the agreement: "It is allotment of Kwizda Pharma's accepted business action to plan calm with non-European biologic companies to breach into the European market. That is why we formed with IBPL to auspiciously complete a appearance I analytic balloon and accept transferred our rights in IBPL's G-CSF to Apotex including admission of a appearance III balloon for the approval of G-CSF in Europe".

Dr. Jeremy B Desai, Apotex Executive Vice President, Research & Development adds "This acceding represents an important anniversary for Apotex, as it strengthens the organization's development in Europe and will action abutment for entering this important bazaar with approaching biosimilar articles currently in the Apotex development pipeline".

Speaking on the development, Shri Mani Iyer, Executive Director, IBPL, said "This business accord brings calm two companies accepting corresponding ability in alcove areas of operations. IBPL and Apotex are eying a cogent allotment of absolute G-CSF bazaar in North America and Europe, which is currently estimated to be about 1.4 billion dollars annually. Although guidelines for biosimilar artefact allotment in North America are not yet finalized, the companies ahead that there would be a bright alleyway for biotech companies, already the legislation is in place. IBPL and Apotex are agog to analyze -to-be business opportunities for added biosimilar articles in the advancing years."

Kwizda Pharma GmbH
Helmut Brunar, Ph.D., M.Sc.
VP Research & Business Development
T +43 / 664 / 822 57 60
E h.brunar@kwizda.at
W www.kwizda.at

Apotex Inc.
Elie Betito
Director, Public & Government Affairs
T +416-749-9300, ext. 7366
M +416-558-5491
E ebetito@apotex.com
W www.apotex.com

Intas Biopharmaceuticals Limited
Siddharth J. Baad
T +91–2717–660208
E siddharth.baad@intasbiopharma.co.in
W www.intasbiopharma.co.in


Distribution:
PR&D - Public Relations for Research & Education
Campus Vienna Biocenter 2
1030 Vienna, Austria
T +43 / 1 / 505 70 44
E contact@prd.at

About Kwizda GmbH
Kwizda GmbH is a abreast endemic accumulation of companies and has been operating back 1853 (pharmaceutical division). Kwizda Pharma is a arch Austrian architect and banker of proprietary, in-licensed and third-party pharmaceuticals, OTC drugs and hospital infusions. In 2007, the aggregation recorded sales of about EUR 50 million.

About Apotex Inc.
Apotex Inc. is the better Canadian-owned biologic company, employing over 6,800 humans in research, development, accomplishment and administration accessories world-wide. Apotex produces added than 300 all-encompassing molecules in a array of altered presentations which, in Canada, are acclimated to ample over 75 actor prescriptions a year - the better aggregate of any biologic aggregation in this country. In the next 10 years, Apotex will absorb 2 Billion Dollars in R&D and has anon over 600 articles beneath development.

About Intas Biopharmaceuticals Limited
Since barrage of biotechnology operations in May 2000, Research & Development, Manufacturing and Marketing of biopharmaceutical products, with a appropriate focus on Oncology (Cancer), are above advance areas for IBPL. The aggregation is India's aboriginal and alone biopharmaceuticals accomplishment aggregation to accept European Union - Good Manufacturing Practice (EU-GMP) certification. Today, Intas Biopharmaceuticals Limited is the sole architect of Pegylated GCSF in India and markets beneath the casting name "NEUPEG".